Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Pelthos Therapeutics Inc.

NYSE: PTHS · Life Sciences · 7 alerts · CIK 1919246

Share price
$7.15Close, Nov 16
Market cap
$28.1M
Shares outstanding
3.93MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Pelthos Therapeutics Inc. filings on SEC EDGAR ↗

7:16 AM ET 10-Q
Financial Results

Pelthos Therapeutics Q3 2026 Results: Net Loss of $7.89M, Loss Narrows

Pelthos Therapeutics reported total revenue of $41.9 million for the nine months ended September 30, 2026, a significant increase from $7.4 million in the prior year. Despite the revenue growth, the company recorded a net loss of $56.4 million due to high selling, general, and administrative expenses and a $9.3 million loss from the change in fair value of convertible debt.

Key figure
Net loss $7.89M
7:10 AM ET 8-K
Financial Results

Pelthos Therapeutics Financial Results

Pelthos Therapeutics reported Q3 2026 financial results, highlighted by Zelsuvmi net product revenue of $15.2 million, a 114% increase year-over-year. The company also highlighted its pending transformative merger with Castle Creek Biosciences, which was announced in October 2026 to create a diversified biotechnology company focused on skin diseases.

“Zelsuvmi delivered another solid quarter, generating net product revenue of $15.2 million. Thousands of patients have already benefited from Zelsuvmi and we remain focused on driving Zelsuvmi growth and building on our success with the planned launches of Xepi® targeted in the first quarter of 2027 and Xeglyze® targeted in the third quarter of 2027.”

Scott Plesha, CEO of Pelthos

“In October, after the close of the third quarter, we took an important step in our pursuit of long-term value by announcing our agreement to combine with Castle Creek, a transaction that we believe will create a stronger, more diversified biotechnology company.”

Scott Plesha, CEO of Pelthos
9:18 AM ET 8-K
M&A Deal

Pelthos Therapeutics M&A Deal with Castle Creek Biosciences, Inc.

Pelthos Therapeutics has entered into a definitive agreement to acquire Castle Creek Biosciences in a merger transaction. Castle Creek stockholders will receive 5.2 million shares of Pelthos common stock plus potential milestone payments totaling up to $300 million tied to the clinical and commercial success of the D-Fi gene therapy franchise. The deal combines Pelthos' commercial dermatology infrastructure with Castle Creek's late-stage cell and gene therapy platform for rare skin diseases.

Counterparty
Castle Creek Biosciences, Inc.
5:54 PM ET Form 4
Insider Selling

Pelthos Therapeutics Insider Peter Greenleaf Sells $16.9K of Stock

Peter Greenleaf sold 797 shares of Pelthos Therapeutics Inc. at $21.17 a share, worth $16.9K in total on Oct 2, 2026. Shares held after the trade: 23,087 (-3.3%).

Value
$16.9K
Shares
797
Price
$21.17
Holding change
-3.3%
Trade date
Oct 2, 2026
5:54 PM ET Form 4
Insider Selling

Pelthos Therapeutics Insider Ezra M. Friedberg Sells $11.6K of Stock

Ezra M. Friedberg sold 558 shares of Pelthos Therapeutics Inc. at $20.72 a share, worth $11.6K in total on Oct 2, 2026. Shares held after the trade: 80,484 (-0.7%).

Value
$11.6K
Shares
558
Price
$20.72
Holding change
-0.7%
Trade date
Oct 2, 2026
5:54 PM ET Form 4
Insider Selling

Pelthos Therapeutics Insider Matthew Pauls Sells $16.5K of Stock

Matthew Pauls sold 786 shares of Pelthos Therapeutics Inc. at $21.00 a share, worth $16.5K in total on Oct 2, 2026. Shares held after the trade: 13,578 (-5.5%).

Value
$16.5K
Shares
786
Price
$21.00
Holding change
-5.5%
Trade date
Oct 2, 2026
5:15 PM ET 8-K
Shareholder Meeting

Pelthos Therapeutics Shareholder Meeting

Pelthos Therapeutics held its 2026 Annual Meeting of Stockholders where shareholders elected eight directors to serve until the 2027 meeting and ratified Grant Thornton LLP as the independent auditor for fiscal year 2026. Additionally, stockholders approved the 2026 Equity Incentive Plan, which replaces the company's previous 2023 plan.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.